|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...345678910111213...5253» |
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment change, Trial termination, Trial primary completion date: A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Mar 3, 2017
P1, N=47, Terminated, Sponsor: Weill Medical College of Cornell University
N=30 --> 47 | Recruiting --> Terminated | Trial primary completion date: Mar 2011 --> Dec 2017
- dasatinib / Generic mfg.
Enrollment change, Trial primary completion date: Dasatinib in Polycythemia Vera (clinicaltrials.gov) - Mar 3, 2017
P2, N=10, Completed, Sponsor: Weill Medical College of Cornell University
N=30 --> 47 | Recruiting --> Terminated | Trial primary completion date: Mar 2011 --> Dec 2017 N=24 --> 10 | Trial primary completion date: Oct 2009 --> Aug 2010
- | arsenic trioxide / Generic mfg., cytarabine / Generic mfg.
Enrollment change, Combination therapy: Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML (clinicaltrials.gov) - Mar 3, 2017
P1/2, N=87, Completed, Sponsor: Weill Medical College of Cornell University
N=24 --> 10 | Trial primary completion date: Oct 2009 --> Aug 2010 N=120 --> 87
- | Trial completion, Trial primary completion date: Pilot Project: Fast Whole-body Spect Scanning to Improve the Detection of Bone Metastases in Patients With Diagnosed Cancer (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=50, Completed, Sponsor: University of British Columbia
N=120 --> 87 Suspended --> Completed | Trial primary completion date: Aug 2011 --> Aug 2016
- | arsenic trioxide / Generic mfg., cytarabine / Generic mfg.
Trial completion, Trial initiation date, Combination therapy, Metastases: Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis (clinicaltrials.gov) - Mar 3, 2017
P, N=21, Completed, Sponsor: Weill Medical College of Cornell University
Suspended --> Completed | Trial primary completion date: Aug 2011 --> Aug 2016 Active, not recruiting --> Completed | Initiation date: Dec 2007 --> Feb 2008
- | Qinprezo (vosaroxin) / Denovo
Enrollment closed: Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy (clinicaltrials.gov) - Mar 3, 2017
P1/2, N=40, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | Initiation date: Dec 2007 --> Feb 2008 Recruiting --> Active, not recruiting
- || tosedostat (CHR-2797) / SOBI
Trial primary completion date: Study of Clinical Efficacy and Safety of Tosedostat in MDS (clinicaltrials.gov) - Mar 3, 2017
P2, N=80, Recruiting, Sponsor: Weill Medical College of Cornell University
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Mar 2018
- |||| Daurismo (glasdegib) / Pfizer
Enrollment open: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Feb 28, 2017
P2, N=222, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2017 --> Mar 2018 Active, not recruiting --> Recruiting
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
Trial completion, Trial primary completion date: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Feb 27, 2017
P2, N=18, Completed, Sponsor: Galena Biopharma, Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2016
- | Xofigo (radium Ra-223 dichloride) / Bayer
Phase classification, FDG PET, Metastases: NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Feb 23, 2017
P1, N=15, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2016 Phase classification: P=N/A --> P1
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Feb 23, 2017
P2, N=61, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P=N/A --> P1 Trial primary completion date: Dec 2016 --> Dec 2013
- ||| imatinib / Generic mfg.
Enrollment closed: IDEAL: A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients (clinicaltrials.gov) - Feb 23, 2017
P4, N=150, Active, not recruiting, Sponsor: Dong-A ST Co., Ltd.
Trial primary completion date: Dec 2016 --> Dec 2013 Recruiting --> Active, not recruiting
- | Trial initiation date: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (clinicaltrials.gov) - Feb 23, 2017
P2, N=30, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Initiation date: Jan 2017 --> Apr 2017
- | fludarabine IV / Generic mfg.
Trial completion: Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (clinicaltrials.gov) - Feb 20, 2017
P1, N=2, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Jan 2017 --> Apr 2017 Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, IO biomarker: Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Feb 15, 2017
P1/2, N=7, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=35 --> 7
- ||| Daurismo (glasdegib) / Pfizer
Enrollment closed: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Feb 13, 2017
P2, N=222, Active, not recruiting, Sponsor: Pfizer
N=35 --> 7 Recruiting --> Active, not recruiting
- Trial completion, Metastases: T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Feb 12, 2017
P1, N=39, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, plerixafor / Generic mfg.
Trial completion: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (clinicaltrials.gov) - Feb 11, 2017
P2, N=48, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Minimal residual disease: Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 11, 2017
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=54 --> 42
- ||||||| Promacta (eltrombopag) / Novartis
Trial completion, Trial initiation date, Combination therapy: A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Feb 9, 2017
P3, N=355, Completed, Sponsor: Novartis Pharmaceuticals
N=54 --> 42 Terminated --> Completed | Initiation date: Jun 2014 --> Feb 2010
- Campath (alemtuzumab) / Sanofi
Trial completion: A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 8, 2017
P2, N=40, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Terminated --> Completed | Initiation date: Jun 2014 --> Feb 2010 Active, not recruiting --> Completed
- || Qinprezo (vosaroxin) / Denovo
Phase classification, Enrollment change, Trial primary completion date, Metastases: Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies (clinicaltrials.gov) - Feb 8, 2017
P1b, N=75, Completed, Sponsor: Sunesis Pharmaceuticals
Active, not recruiting --> Completed Phase classification: P1 --> P1b | N=30 --> 75 | Trial primary completion date: Aug 2008 --> Dec 2008
- || Daurismo (glasdegib) / Pfizer
Trial primary completion date: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Feb 7, 2017
P2, N=222, Recruiting, Sponsor: Pfizer
Phase classification: P1 --> P1b | N=30 --> 75 | Trial primary completion date: Aug 2008 --> Dec 2008 Trial primary completion date: Oct 2017 --> Dec 2016
- |||| lenalidomide / Generic mfg.
Trial completion, Monotherapy: Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 6, 2017
P2, N=215, Completed, Sponsor: Celgene Corporation
Trial primary completion date: Oct 2017 --> Dec 2016 No longer recruiting --> Completed
- Trial termination: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=30, Terminated, Sponsor: Rutgers, The State University of New Jersey
No longer recruiting --> Completed Active, not recruiting --> Terminated; slow accrual
- gedatolisib (PF-05212384) / Celcuity
Enrollment closed, Enrollment change, Trial initiation date: LAM-PIK: PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Feb 3, 2017
P2, N=10, Active, not recruiting, Sponsor: Institut Curie
Active, not recruiting --> Terminated; slow accrual Recruiting --> Active, not recruiting | N=39 --> 10 | Initiation date: Jun 2015 --> Aug 2015
- cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Trial primary completion date: Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 1, 2017
P2, N=81, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=39 --> 10 | Initiation date: Jun 2015 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Apr 2019 --> Jan 2017
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial initiation date, Trial termination, Trial primary completion date: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (clinicaltrials.gov) - Feb 1, 2017
P2, N=9, Terminated, Sponsor: Sherif S. Farag
Active, not recruiting --> Completed | Trial primary completion date: Apr 2019 --> Jan 2017 Initiation date: Dec 2007 --> Aug 2007 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> May 2016; Slow accrual
- imatinib / Generic mfg.
Enrollment change, Trial withdrawal: abl LMC: Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=0, Withdrawn, Sponsor: Centre Hospitalier Universitaire de N?mes
Initiation date: Dec 2007 --> Aug 2007 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> May 2016; Slow accrual N=120 --> 0 | Suspended --> Withdrawn
- Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 31, 2017
P1/2, N=50, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=120 --> 0 | Suspended --> Withdrawn Trial primary completion date: Dec 2016 --> Dec 2017
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 30, 2017
P1, N=19, Active, not recruiting, Sponsor: Bruno C. Medeiros
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2019
- decitabine / Generic mfg.
Trial primary completion date: Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 30, 2017
P2, N=125, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2016 --> Dec 2019 Trial primary completion date: May 2017 --> Apr 2018
- Xofigo (radium Ra-223 dichloride) / Bayer
Trial primary completion date, FDG PET, Metastases: NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=15, Recruiting, Sponsor: Stanford University
Trial primary completion date: May 2017 --> Apr 2018 Trial primary completion date: Apr 2017 --> Apr 2018
- adavosertib (AZD1775) / AstraZeneca, Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Trial primary completion date, Combination therapy: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 30, 2017
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2017 --> Apr 2018 N=13 --> 30 | Trial primary completion date: Oct 2016 --> Aug 2018
- cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial primary completion date: Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jan 26, 2017
P2, N=81, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=13 --> 30 | Trial primary completion date: Oct 2016 --> Aug 2018 Trial primary completion date: Apr 2018 --> Apr 2019
- | bortezomib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation (clinicaltrials.gov) - Jan 26, 2017
P2, N=15, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2018 --> Apr 2019 Active, not recruiting --> Completed | N=40 --> 15 | Trial primary completion date: Aug 2018 --> Jan 2017
- Vonjo (pacritinib) / SOBI
Enrollment change, Trial termination, Trial primary completion date: Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) (clinicaltrials.gov) - Jan 26, 2017
P2, N=4, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=40 --> 15 | Trial primary completion date: Aug 2018 --> Jan 2017 N=40 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Jan 2017
- || Trial primary completion date: A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (? 65 Years) With Haematologic Neoplasms (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=80, Recruiting, Sponsor: Celgene
N=40 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Jan 2017 Trial primary completion date: Nov 2016 --> Feb 2017
- Coversin SC (nomacopan SC) / Akari Therap
Trial primary completion date: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) (clinicaltrials.gov) - Jan 24, 2017
P2, N=6, Recruiting, Sponsor: AKARI Therapeutics
Trial primary completion date: Nov 2016 --> Feb 2017 Trial primary completion date: Dec 2016 --> Dec 2018
- deferasirox tablet for oral suspension / Generic mfg.
Biomarker, Trial termination, Trial primary completion date: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 23, 2017
P2, N=50, Terminated, Sponsor: Haukeland University Hospital
Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jan 2017; Failure to recruit patients with hemochromatosis to the Deferasirox arm
- Trial completion, Trial initiation date, Trial primary completion date: OPBG_359.11: Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=30, Completed, Sponsor: Mariella Enoc
Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jan 2017; Failure to recruit patients with hemochromatosis to the Deferasirox arm Recruiting --> Completed | Initiation date: Sep 2011 --> Jan 2012 | Trial primary completion date: Sep 2013 --> Sep 2016
- Vonjo (pacritinib) / SOBI
Trial primary completion date: Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jan 23, 2017
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Initiation date: Sep 2011 --> Jan 2012 | Trial primary completion date: Sep 2013 --> Sep 2016 Trial primary completion date: Dec 2016 --> Sep 2018
- New trial, Surgery: Cardiac Output and Other Hemodynamic Changes With Prone Position in Cervical Myelopathy Patients Undergoing Surgery (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=30, Completed, Sponsor: Dhritiman Chakrabarti
- | Leukine (sargramostim) / Partner Therap
Trial completion: Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment (clinicaltrials.gov) - Jan 18, 2017
P2, N=0, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Dec 2016 --> Sep 2018 Active, not recruiting --> Completed
- aspirin / Generic mfg., hydroxyurea / Generic mfg.
Trial completion, Trial primary completion date: Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=1398, Completed, Sponsor: University of Cambridge
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, Enrollment change: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Jan 18, 2017
P2, N=21, Active, not recruiting, Sponsor: John Mascarenhas
Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016 Recruiting --> Active, not recruiting | N=86 --> 21
- Jakafi (ruxolitinib) / Incyte, Farydak (panobinostat) / Secura Bio
Enrollment closed, Enrollment change, Trial primary completion date, Epigenetic controller: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (clinicaltrials.gov) - Jan 18, 2017
P1/2, N=18, Active, not recruiting, Sponsor: John Mascarenhas
Recruiting --> Active, not recruiting | N=86 --> 21 Recruiting --> Active, not recruiting | N=58 --> 18 | Trial primary completion date: Dec 2016 --> Dec 2017
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed, Enrollment change: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2017
P=N/A, N=46, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=58 --> 18 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=90 --> 46
- Trial primary completion date: MR-HIFU for Bone Metastases (clinicaltrials.gov) - Jan 12, 2017
P=N/A, N=12, Active, not recruiting, Sponsor: Institute of Cancer Research, United Kingdom
Recruiting --> Active, not recruiting | N=90 --> 46 Trial primary completion date: Dec 2016 --> Apr 2017
- Trial suspension, Metastases: ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS (clinicaltrials.gov) - Jan 12, 2017
P2, N=20, Suspended, Sponsor: Ottawa Hospital Research Institute
Trial primary completion date: Dec 2016 --> Apr 2017 Recruiting --> Suspended